

Special Issue

Mastering the Immunosuppressive Tumor Microenvironment with Cancer Vaccines

Message from the Guest Editor

The tumor microenvironment (TME) is a major obstacle in cancer immunotherapy, largely because it actively suppresses immune responses. To make cancer vaccines more effective, we need innovative ways to disrupt or evade this immunosuppressive barrier. This Special Issue will highlight the latest advances in reprogramming TME to boost the power of both therapeutic and preventive cancer vaccines. We invite the submission of original research and in-depth reviews, covering new vaccine technologies, optimal antigen selection, improved adjuvants, advanced delivery systems, and combination strategies such as pairing vaccines with checkpoint inhibitors, cytokine therapies, or stromal-targeting agents. We are especially interested in studies that bridge lab discoveries with real-world clinical applications. Submissions on topics like tumor-infiltrating immune cells, metabolic and stromal influences on immunity, and personalized vaccine design are highly encouraged. By bringing together cutting-edge research, this Special Issue aims to uncover how cancer vaccines can transform the TME and trigger long-lasting anti-tumor immunity.

Guest Editor

Dr. Prem Prakash Kushwaha
BGES, Cleveland State University, Cleveland, OH, USA

Deadline for manuscript submissions

31 March 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/247169

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)